Biotech, AIInsilico AI-Designed Drug Shows Efficacy in Lung Disease Phase 2a Trial50% center coverage2 sources
Biotech, AIInsilico AI-Designed Drug Shows Efficacy in Lung Disease Phase 2a Trial50% center coverage2 sources
BiotechMerus Shares Surge 40% on Promising Cancer Data Amid Biotech Sector Uncertainty100% center coverage1 source
BiotechMerus Shares Surge 40% on Promising Cancer Data Amid Biotech Sector Uncertainty100% center coverage1 source
BiotechCARVYKTI Achieves 33% Five-Year Progression-Free Survival in Relapsed Multiple Myeloma100% left coverage1 source
BiotechCARVYKTI Achieves 33% Five-Year Progression-Free Survival in Relapsed Multiple Myeloma100% left coverage1 source
Biotech, StartupsRegeneron Acquires 23andMe Assets for $256 Million After Bankruptcy100% left coverage2 sources
Biotech, StartupsRegeneron Acquires 23andMe Assets for $256 Million After Bankruptcy100% left coverage2 sources